These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39071476)

  • 1. Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors.
    Dong Y; Liu M; Wang J; Ding Z; Sun B
    RSC Adv; 2024 Jul; 14(32):23559. PubMed ID: 39071476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors.
    Dong Y; Liu M; Wang J; Ding Z; Sun B
    RSC Adv; 2019 Aug; 9(45):26302-26314. PubMed ID: 35531010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison and analysis of the structures and binding modes of antifungal SE and CYP51 inhibitors.
    Sun B; Huang W; Liu M; Lei K
    J Mol Graph Model; 2017 Oct; 77():1-8. PubMed ID: 28802152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and activity evaluation of novel benzodioxane derivatives as dual-target antifungal inhibitors.
    An Y; Liu W; Xie H; Fan H; Han J; Sun B
    Eur J Med Chem; 2022 Jan; 227():113950. PubMed ID: 34731761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.
    Sun B; Dong Y; Lei K; Wang J; Zhao L; Liu M
    Bioorg Med Chem; 2019 Jun; 27(12):2427-2437. PubMed ID: 30765301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections.
    Zhu T; Chen X; Li C; Tu J; Liu N; Xu D; Sheng C
    Eur J Med Chem; 2021 Oct; 221():113524. PubMed ID: 33992927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.
    Sun B; Zhang H; Liu M; Hou Z; Liu X
    Medchemcomm; 2018 Jul; 9(7):1178-1187. PubMed ID: 30109006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure.
    Liu W; Sun Z; An Y; Liu Y; Fan H; Han J; Sun B
    Eur J Med Chem; 2022 Jan; 228():113972. PubMed ID: 34772530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.
    Sun B; Dong Y; An Y; Liu M; Han J; Zhao L; Liu X
    Eur J Med Chem; 2020 Nov; 205():112645. PubMed ID: 32791399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.
    An Y; Dong Y; Liu M; Han J; Zhao L; Sun B
    Eur J Med Chem; 2021 Jan; 210():112991. PubMed ID: 33183866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies.
    Dong Y; Liu X; An Y; Liu M; Han J; Sun B
    Bioorg Chem; 2020 Jun; 99():103749. PubMed ID: 32220664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.
    An Y; Dong Y; Min L; Zhao L; Zhao D; Han J; Sun B
    ACS Med Chem Lett; 2020 Jun; 11(6):1152-1159. PubMed ID: 32550995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles.
    Elias R; Basu P; Fridman M
    J Med Chem; 2022 Feb; 65(3):2361-2373. PubMed ID: 35084852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CYP51 for drug design by the contributions of molecular modeling.
    Rabelo VW; Santos TF; Terra L; Santana MV; Castro HC; Rodrigues CR; Abreu PA
    Fundam Clin Pharmacol; 2017 Feb; 31(1):37-53. PubMed ID: 27487199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential dual inhibition of SE and CYP51 by eugenol conferring inhibition of Candida albicans: Computationally curated study with experimental validation.
    Prajapati J; Goswami D; Dabhi M; Acharya D; Rawal RM
    Comput Biol Med; 2022 Dec; 151(Pt A):106237. PubMed ID: 36327880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
    Ekins S; Mankowski DC; Hoover DJ; Lawton MP; Treadway JL; Harwood HJ
    Drug Metab Dispos; 2007 Mar; 35(3):493-500. PubMed ID: 17194716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mulberrin inhibits
    Liu L; Wang H; Lin L; Gao Y; Niu X
    Food Funct; 2022 Apr; 13(7):4032-4046. PubMed ID: 35315482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.
    Liu Y; Wang Q; Yu S; Liu M; Han J; Sun B
    J Med Chem; 2023 Oct; 66(19):13838-13857. PubMed ID: 37752076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
    Han G; Liu N; Li C; Tu J; Li Z; Sheng C
    J Med Chem; 2020 May; 63(10):5341-5359. PubMed ID: 32347094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.
    Liu W; Liu Y; Fan H; Liu M; Han J; An Y; Dong Y; Sun B
    J Med Chem; 2022 Sep; 65(18):12219-12239. PubMed ID: 36074863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.